The ALS Society of Manitoba is proud to celebrate Nitesh Sanghai, University of Manitoba PhD candidate and valued member of our Board of Directors, for receiving the prestigious Mitacs Innovation Award.
Nitesh co-invented a promising new ALS drug candidate called Borsantrazole, designed to offer an improved version of Edaravone, one of the few existing treatments that can slow ALS progression. Early pre-clinical results show excellent safety and effectiveness in ALS model studies.
Originally from Jharia, India, Nitesh’s inspiring journey—from being the first in his family to complete Grade 10 to pursuing advanced research in Canada—reflects the passion and determination he brings to ALS innovation. His goal is to help move this potential treatment “from bench to bedside,” making future therapies more effective and affordable for Canadians living with ALS.
We are honoured to have Nitesh’s expertise, dedication, and heart contributing to our mission.
Read the full article in the Winnipeg Free Press!
